Aug. 20, 2008 — A variation gene causes more than 60% of cases of a serious side impact of cholesterol-lowering statin drugs — muscle pain and weakness.
Statin drugs — Lipitor, Pravachol, Crestor, Lescol, Mevacor, and Zocor — are considered surprisingly secure. But one in each 10,000 patients per year develops drug-related muscle inconvenience. Very seldom, this myopathy leads to muscle breakdown and lethal kidney failure.
Oxford University analyst Rory Collins, MB, and the Search Collaborative Bunch performed genome-wide checks of heart attack survivors taking high measurements (80 mg/day) of Zocor in a large-scale clinical trial. They compared the 98 patients who created myopathy with 98 patients who did not.
“We provide compelling evidence that at least one common variation in the SLCO1B1 quality considerably changes the chance of [Zocor]-induced myopathy,” Collins and colleagues conclude. “These discoveries are likely to apply to other statins because myopathy may be a course impact, and SLCO1B1 polymorphisms influence the blood levels of several statins.”
The gene variant is relatively common. It changes the work of a gene that directs medicate uptake within the liver. Individuals who acquire two duplicates of the gene had a 17-fold expanded hazard of muscle issues when taking high dosages of Zocor. Those with fair a single copy had a 4.5-fold expanded hazard.
Collins and colleagues recommend that some time recently starting high-dose statin treatment, patients may advantage from hereditary testing to see whether they are at risk of side effects.
Yusuke Nakamura, MD, PhD, director of the Human Genome Center at the College of Tokyo, agrees.
In a writing going with the Collins team’s report within the Aug. 21 issue of the Modern England Diary of Pharmaceutical, Nakamura recommends that avoiding tall measurements of statins in individuals who carry the gene may reduce statin-related muscle problems by 60%.